Enzyme might be target for treating smoking, alcoholism at same time

September 12, 2011

An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, according to a study by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco.

Over the course of four weeks, mice genetically engineered to lack the gene for (PKC) epsilon consumed less of a nicotine-containing water solution than normal mice, and were less likely to return to a chamber in which they had been given nicotine.

In contrast, normal mice steadily increased their consumption of nicotine solution while the mice lacking PKC epsilon did not.

The study was conducted by Gallo senior associate director and investigator Robert O. Messing, MD, UCSF professor of neurology, and Gallo researcher Anna M. Lee, PhD.

In normal mice, as in humans, nicotine binds to a certain class of nicotinic receptors located on dopamine neurons, which causes dopamine to be released in the brain. Dopamine creates a feeling of enjoyment, and thus prompts a sense of reward. Lee and Messing found that mice lacking PKC epsilon are deficient in these nicotinic receptors.

The study appears in the online Early Edition of the for the week of September 12, 2011.

The finding complements earlier research in which Messing found that mice genetically engineered to lack the PKC epsilon enzyme drank less alcohol than normal mice and were disinclined to return to a chamber in which they had been given alcohol.

"This could mean that these mice might not get the same sense of reward from nicotine or alcohol," said Messing. "The enzyme looks like it regulates the part of the reward system that involves these ." The reward system is a complex of areas in the brain that affect craving for nicotine, alcohol and other addictive substances.

The next step in the research, said Messing, would be to develop compounds that inhibit epsilon. The ultimate goal, he said, would be medications that could be used "to take the edge off of addiction by helping people get over some of their reward craving."

More information: “Protein kinase C epsilon modulates nicotine consumption and dopamine reward signals in the nucleus accumbens,” by Anna M. Lee and Robert O. Messing, PNAS.

Related Stories

Recommended for you

Flow means 'go' for proper lymph system development

July 27, 2015

The lymphatic system provides a slow flow of fluid from our organs and tissues into the bloodstream. It returns fluid and proteins that leak from blood vessels, provides passage for immune and inflammatory cells from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.